Loading organizations...

§ Venture Capital · 9400 Garsington Road, Oxford, OX4 2HN, UK
Woodford Patient Capital Trust operates as a publicly listed investment vehicle, dedicated to long-term capital appreciation through early-stage and growth companies, predominantly within the United Kingdom. It focuses on unlisted and illiquid assets, embodying a "patient capital" philosophy to support innovative businesses over extended periods, thereby unlocking value in promising enterprises.
The trust was established in 2015 by Neil Woodford, a prominent fund manager. His founding insight addressed a market gap for patient capital, enabling innovative UK companies to mature and scale without premature pressure for short-term returns, reflecting his long-standing investment philosophy.
Its offering targets investors seeking exposure to a diversified portfolio of high-growth potential businesses, particularly those not yet accessible via mainstream public markets. The trust's vision is to be a crucial funding partner for emerging UK innovators, providing the stable capital base required to foster significant advancements and deliver substantial long-term returns.
Woodford Patient Capital Trust has 7 tracked investments across 5 companies. The latest tracked deal is $53.0M Series B in Inivata in March 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2019 | Inivata | $53.0M Series B | — | Cambridge Innovation Capital, Johnson & Johnson Innovation, RT Ventures |
| Jan 28, 2018 | Bodle Technologies | $8.5M Series A | Parkwalk Advisors | Oxford Science Enterprises, Oxford Technology And Innovations |
| Nov 24, 2016 | Kymab | $100.9M Series C | Simone Song | Bill & Melinda Gates Foundation, CF Woodford Equity Income Fund, Malin Corporation, Shenzhen Hepalink Pharmaceutical |
| Feb 2, 2016 | MISSION Therapeutics | $86.4M Other Equity | Imperial Innovations, Woodford Patient Capital Trust | Pfizer, Roche, Sofinnova Partners, SR ONE |
| Jan 1, 2016 | Inivata | $45.0M Series A | — | Cambridge Innovation Capital, Imperial Innovations, Johnson & Johnson Innovation |
| Jul 29, 2015 | Seedrs | $15.6M Series A | TIM Levene, Woodford Patient Capital Trust | — |
| May 6, 2015 | Kymab | $50.0M Series B Extension | Adrian Howd, Woodford Patient Capital Trust | — |